S C M Stoof1, M H Cnossen2, M P M de Maat1, F W G Leebeek1, M J H A Kruip1. 1. Department of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands. 2. Department of Paediatric Haematology and Oncology, Erasmus University Medical Centre/ Sophia Children's Hospital, Rotterdam, The Netherlands.
Abstract
INTRODUCTION: Desmopressin is frequently used in patients with bleeding disorders because of its prohaemostatic effects. In recent years desmopressin use increased due to reported high incidence of inhibitors in mild haemophilia after clotting factor infusion and the rising costs of clotting factor concentrates. The safety and frequency of side effects have hardly been assessed in well-designed studies. AIM: We therefore prospectively evaluated side effects of desmopressin in a large unselected cohort of bleeding disorder patients, who received a desmopressin test dose. METHODS: Blood was drawn prior to, one, three, six and 24 h after desmopressin. Primary outcome was change in serum sodium, haematocrit, serum- and urine osmolality, body weight and vital signs. Self-reported side effects were evaluated as secondary outcome. RESULTS: In total, 108 patients were included, median age 30 years, the majority of whom had von Willebrand disease type 1 (76%). A significant change in water balance parameters was observed. Four patients (4%) had hyponatraemia (≤135 mmol L(-1) ) after 24 h but no severe hyponatraemia occurred (≤125 mmol L(-1) ). After infusion, 41 (38%) patients were hypotensive (≤90 mmHg SBP and/or ≤60 mmHg DBP) and 10 (9%) presented with tachycardia (>100 min(-1) ). However, none of these effects sustained at 24 h. Infusion was discontinued in one patient because of tachycardia, nausea and malaise. Self-reported side effects included: headache, fatigue, flush and dizziness. CONCLUSION: Observed side effects correspond with the known antidiuretic and vasomotor effects of desmopressin. Changes in parameters were temporary and not clinically relevant. In conclusion, our study supports desmopressin use as a safe treatment option in patients with various bleeding disorders.
INTRODUCTION: Desmopressin is frequently used in patients with bleeding disorders because of its prohaemostatic effects. In recent years desmopressin use increased due to reported high incidence of inhibitors in mild haemophilia after clotting factor infusion and the rising costs of clotting factor concentrates. The safety and frequency of side effects have hardly been assessed in well-designed studies. AIM: We therefore prospectively evaluated side effects of desmopressin in a large unselected cohort of bleeding disorderpatients, who received a desmopressin test dose. METHODS: Blood was drawn prior to, one, three, six and 24 h after desmopressin. Primary outcome was change in serum sodium, haematocrit, serum- and urine osmolality, body weight and vital signs. Self-reported side effects were evaluated as secondary outcome. RESULTS: In total, 108 patients were included, median age 30 years, the majority of whom had von Willebrand disease type 1 (76%). A significant change in water balance parameters was observed. Four patients (4%) had hyponatraemia (≤135 mmol L(-1) ) after 24 h but no severe hyponatraemia occurred (≤125 mmol L(-1) ). After infusion, 41 (38%) patients were hypotensive (≤90 mmHg SBP and/or ≤60 mmHg DBP) and 10 (9%) presented with tachycardia (>100 min(-1) ). However, none of these effects sustained at 24 h. Infusion was discontinued in one patient because of tachycardia, nausea and malaise. Self-reported side effects included: headache, fatigue, flush and dizziness. CONCLUSION: Observed side effects correspond with the known antidiuretic and vasomotor effects of desmopressin. Changes in parameters were temporary and not clinically relevant. In conclusion, our study supports desmopressin use as a safe treatment option in patients with various bleeding disorders.
Authors: Nathan T Connell; Veronica H Flood; Romina Brignardello-Petersen; Rezan Abdul-Kadir; Alice Arapshian; Susie Couper; Jean M Grow; Peter Kouides; Michael Laffan; Michelle Lavin; Frank W G Leebeek; Sarah H O'Brien; Margareth C Ozelo; Alberto Tosetto; Angela C Weyand; Paula D James; Mohamad A Kalot; Nedaa Husainat; Reem A Mustafa Journal: Blood Adv Date: 2021-01-12
Authors: Lisette M Schütte; Marjon H Cnossen; Reinier M van Hest; Mariette H E Driessens; Karin Fijnvandraat; Suzanne Polinder; Erik A M Beckers; Michiel Coppens; Jeroen Eikenboom; Britta A P Laros-van Gorkom; Karina Meijer; Laurens Nieuwenhuizen; Evelien P Mauser-Bunschoten; Frank W G Leebeek; Ron A A Mathôt; Marieke J H A Kruip Journal: BMJ Open Date: 2019-04-23 Impact factor: 2.692
Authors: Lisette M Schütte; Luca S Hodes; Iris van Moort; Sara C M Stoof; Frank W G Leebeek; Marjon H Cnossen; Moniek P M de Maat; Marieke J H A Kruip Journal: Haemophilia Date: 2020-07-26 Impact factor: 4.287
Authors: Anne-Fleur Zwagemaker; Fabienne R Kloosterman; Michiel Coppens; Samantha C Gouw; Sara Boyce; Catherine N Bagot; Erik A M Beckers; Paul Brons; Giancarlo Castaman; Jeroen Eikenboom; Shannon Jackson; Marieke J H A Kruip; Frank W G Leebeek; Karina Meijer; Laurens Nieuwenhuizen; Ingrid Pabinger; Karin Fijnvandraat Journal: Res Pract Thromb Haemost Date: 2022-08-31